17,261 trials
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8 · Anatomic Stage IB Breast Cancer AJCC v8
Primary: Incidence of Adverse Events (Phase I) — 3; 3; 6 Participants
Bladder Cancer
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 2; 2; 1; 3 Participants
Atopic Asthma
Primary: Number of Subjects With Serious Adverse Events — 0; 0 participants
Anterior Cruciate Ligament Tear · Anterior Cruciate Ligament Rupture
Primary: Change in Synovial Interleukin (IL) -1 Receptor Antagonist Concentration — 13.8; 16; 9.9; 7.5 pg/ml
Advanced Rare Tumours
Primary: Objective Response Rate Measured by RECIST Version 1.1 — 1; 19; 32; 76 Participants
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Percent of Participants With 6-month Progression-free Survival (PFS6) — 33 percent of participants
Covid19
Primary: Number of Subjects With Serious Adverse Events — 0; 1 Participants
Classical Hodgkin Lymphoma · Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 0.05 Proportion of participants
Ewing Sarcoma · PEComa · Epithelioid Sarcoma
Primary: Maximum Tolerated Dose of ABI-009 — 100 mg/m^2
Biliary Atresia
Primary: Mean Change in Total Serum Bilirubin Levels — -3.5; -3.11 mg/dl — p=0.7419
Jansky-Bielschowsky Disease · Batten Disease · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Primary: Motor Language (ML) Scale: Rate of Decline in the 0 to 6-point ML Score. — 0.15; 1.30 change in score/48 wk — p=< 0.0001
Acromegaly
Primary: Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level — -0.034 ng/mL x ULN — p=0.6285
Alzheimer's Disease · Cognitive Impairment · Tauopathies
Primary: Overview of Treatment-Emergent Adverse Events, Safety Set — 6; 17; 6; 8 Participants
Gastrointestinal Stromal Tumors
Primary: Part 1: Recommended Phase 2 Dose (RP2D) of CGT9486 — 1000 mg
CML · Chronic Myelogenous Leukemia · Leukemia, Myeloid Chronic
Primary: Molecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone — 19.0; 28.6; 0.0 Percentage of participants